Baird lowered the firm’s price target on Dianthus (DNTH) to $50 from $58 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated it product pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
- Dianthus Therapeutics Reports Increased R&D Expenses
- Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
- Dianthus completes enrollment for Phase 2 MaGic Trial of DNTH103
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge